Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Ketamine voor gecombineerde depressie en alcoholgebruiksstoornis (KeDA)

14 november 2026 bijgewerkt door: Andreas Wahl Blomkvist, University Hospital of North Norway

Ketamine voor gecombineerde depressie en alcoholgebruiksstoornis: een geblindeerde gerandomiseerde actieve placebogecontroleerde studie (de KeDA-studie)

The goal of this clinical trial is to investigate the effects of ketamine, in combination with standard inpatient addiction therapy, for adults with depression and alcohol use disorder. After screening and enrollment, participants will undergo baseline assessments of depression, measures of alcohol use and craving, as well as neurocognitive function. Participants will then be randomized to either ketamine (intervention) or midazolam (control). All participants will be admitted for standard inpatient addiction therapy while receiving ketamine or midazolam. Measures on safety, depression and alcohol use disorder will be repeatedly assessed during and after treatment. Final follow-up assessment is scheduled 6 months after baseline assessment.

Studie Overzicht

Gedetailleerde beschrijving

Depression and alcohol use disorder (AUD) often coexist and can create significant challenges for individuals seeking effective treatment. Traditional treatment approaches have shown limited success in addressing both conditions simultaneously. Ketamine has shown to have promising rapid antidepressant effects and a possible role in the treatment of substance use disorders. By targeting both depression and AUD simultaneously, ketamine has the potential to offer dual benefits, improving depressive symptoms while addressing alcohol cravings or consumption. Furthermore, rapid relief from depressive symptoms may enhance motivation for recovery, reduce the risk of relapse, and improve overall treatment engagement and outcomes. Although ketamine is generally considered safe when administered under medical supervision, the safety profile in individuals with comorbid depression and AUD needs further investigation. The overall objective of this study is to examine the safety and efficacy of ketamine on adults with depression and AUD that are admitted for standard inpatient addiction therapy.

The study will only include adults with at least moderate depression and alcohol use disorder as their primary substance use disorder that are admitted for inpatient addiction therapy. Participants that are unable to give informed consent or have contraindication(s) for ketamine will be excluded.

After screening and enrollment, participants will undergo baseline assessments with measures on depression (using Montgomery-Åsberg Depression Rating Scale (MADRS) and Beck Depression Inventory-II (BDI-II)), alcohol use (using Timeline Follow-Back method (TLFB)), alcohol craving (using Short version of Alcohol Craving Questionnaire (ACQ-Short) and Penn Alcohol Craving Scale (PACS)) and neurocognitive function (using Cambridge Neuropsychological Test Automated Battery (CANTAB)). Participants will then be randomized to intervention group or control group. The intervention group will receive ketamine as four single doses, given biweekly for two weeks. The control group will receive midazolam as active placebo. Participants will undergo several follow-up assessments after treatment (1-2 day(s), 1 week, 2 weeks and 4 weeks after treatment). Final follow-up assessment will be 6 months after baseline.

By using open questions and specific instruments for assessing adverse effects associated with ketamine (using modified version of Ketamine Side Effect Tool (mKSET)), the trial will assess the frequency, severity and duration of any adverse events and severe adverse events. All adverse events will be evaluated with regards to its causal relationship to ketamine. In addition, physician-assessed and patient-assessed tolerability will be registered. Changes in neurocognitive function from baseline will be assessed after treatment.

Changes in depression will be measured several times using rater-blinded MADRS-assessment and self-report instrument (BDI-II). Measures of alcohol use (TLFB), alcohol craving (ACQ-short and PACS), relapse risk and time until relapse will used as measures on alcohol use disorder following treatment. Several exploratory objectives will be examined, including changes in alcohol dependence severity (using Severity of Alcohol Dependence Questionnaire (SADQ)), changes in quality of life (using World Health Organizations brief quality of life questionnaire (WHOQOL-BREF)), changes in self-reported treatment effectiveness (using Treatment Effectiveness Assessment (TEA)) and changes in anxiety (using Generalized Anxiety Disorder scale (GAD-7)). Finally, data on the subjective experience of the treatment (using Ego Dissolution Inventory (EDI), Emotional Breakthrough Inventory (EBI) and Mystical Experience Questionnaire (MEQ30)) will be collected and used in a regression model with baseline measures to assess predictors of treatment response on measures of depression and AUD .

Studietype

Ingrijpend

Inschrijving (Geschat)

34

Fase

  • Fase 2
  • Fase 1

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

      • Moss, Noorwegen, 1535
        • Nog niet aan het werven
        • Department of Addiction Treatment, ØHT
        • Contact:
        • Hoofdonderzoeker:
          • Mina Piiksi Dahli, PhD, M.D.
      • Tromsø, Noorwegen
        • Werving
        • Department of Addiction, University Hospital of North Norway
        • Contact:

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 65 jaar (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Please contact the project team for a full and detailed list of inclusion/exclusion criteria

Inclusion Criteria:

  • Currently abstinent from alcohol
  • At least moderate depression without psychotic features
  • Minimum Montgomery-Åsberg Depression Rating Scale (MADRS) of 20
  • Alcohol dependence
  • Admitted for inpatient addiction therapy at University Hospital of North Norway or Østfold Hospital Trust

Exclusion Criteria:

  • Intoxicated or in significant withdrawal from alcohol or drug use
  • Not able to give adequate informed consent
  • Current or past history of schizophrenia, schizophreniform disorder, paranoid delusional disorder, schizoaffective disorder
  • Current or historical diagnosis of schizophrenia in a first degree relative
  • Cardiovascular conditions: recent stroke (< 1 year from informed consent), recent myocardial infarction (< 1 year from informed consent), uncontrolled hypertension (>150/100 mm Hg) or recent arrhythmia (< 1 year from informed consent; clinically significant arrhythmia requiring treatment at hospital)
  • Liver (Child-Pughs Class C) or kidney (Creatinin clearance < 30 mL/min) failure
  • Heart failure (the New York Heart Association Functional Classification (NYHA) class III or IV)
  • Chronic respiratory failure (requiring long-term oxygen therapy (LTOT) and/or Global Initiative for Chronic Obstructive Lung Disease system (GOLD) stage 3 or higher)
  • Previous anaphylactic reaction to ketamine or midazolam
  • Illegal use of ketamine the last 6 months
  • Pregnancy or breastfeeding
  • Current or suspected increased intracranial pressure

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Verdrievoudigen

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention group

Ketamine, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,8 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

Actieve vergelijker: Control group

Midazolam, 0,8 mg/kg body weight, given as four single doses (biweekly for two weeks)

Four single-doses, given two times per week for two weeks Dose: 0,02 mg/kg body weight Route of administration: intravenous infusions over 40 minutes

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Depression
Tijdsspanne: Within 3 days after final treatment session

Change from baseline using rater-blinded Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

Within 3 days after final treatment session

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Alcohol craving tonic
Tijdsspanne: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Penn Alcohol Craving Scale (PACS) (range 0-30; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Alcohol craving phasic
Tijdsspanne: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Alcohol Craving Questionnaire - Short version (ACQ-short) (range 12-84; higher score indicate worse outcome)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Depression response/remission
Tijdsspanne: Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session

Rates of response (50% or more reduction in MADRS from baseline) and remission (9 points or less in MADRS)

Repeated measurements from baseline and 1 day, 1 week, 2 weeks and 4 weeks after final treatment session
Relapse risk
Tijdsspanne: From baseline until 6 months after baseline

Incidence of relapse in each group (defined as two or more consecutive heavy drinking days)

From baseline until 6 months after baseline
Time until relapse
Tijdsspanne: From baseline until 3 and 6 months after baseline

Average time from final treatment session until relapse

From baseline until 3 and 6 months after baseline

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Duration of antidepressant effect (blinded-rater assessed)
Tijdsspanne: From baseline until 6 months after baseline

Change in Montgomery-Åsberg Depression Rating Scale (MADRS) (range 0-60; higher score indicate worse outcome)

From baseline until 6 months after baseline
Duration of antidepressant effect (self-report)
Tijdsspanne: From baseline until 6 months after baseline

Change in the Beck Depression Inventory-II (BDI-II) (Range 0-63; higher score indicate worse outcome)

From baseline until 6 months after baseline
Tolerability using the ketamine side effect tool (KSET)
Tijdsspanne: Up to 1 month

Physician-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Tolerability using the ketamine side effect tool (KSET)
Tijdsspanne: Up to 1 month

Patient-reported tolerability of each treatment session (good, moderate and poor)

Up to 1 month
Cambridge Neuropsychological Test Automated Battery (CANTAB): Stop Signal Task (SST); Spatial Working Memory (SWM) task; Intra-Extra Dimensional Shift (IED) task; Paired Associates Learning (PAL) task; Emotional Bias Task (EBT)
Tijdsspanne: Within 3 days after final treatment session

Assess within- and between-group changes in neurocognitive function from baseline to within three days from the final treatment session: SST (Range 0-1000; Lower score indicate better outcome); SWM (Range: 2-14; Lower score indicates better outcome); IED (Range: 0-402; Lower score indicates better outcome); PAL (Range: 0-70; Lower score indicates better outcome); EBT (Range: 0-15; Higher score indicates better outcome (more happy))

Within 3 days after final treatment session
Adverse reaction frequency
Tijdsspanne: Up to 6 months

Frequency of adverse reactions

Up to 6 months
Adverse reaction severity
Tijdsspanne: Up to 6 months

Number of mild, moderate and severe adverse reactions

Up to 6 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Studie directeur: Ole K Grønli, Assoc Prof, University Hospital of North Norway
  • Hoofdonderzoeker: Andreas W Blomkvist, M.D., University Hospital of North Norway

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Nuttige links

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 januari 2025

Primaire voltooiing (Geschat)

1 juli 2028

Studie voltooiing (Geschat)

1 juli 2028

Studieregistratiedata

Eerst ingediend

1 juli 2023

Eerst ingediend dat voldeed aan de QC-criteria

16 oktober 2023

Eerst geplaatst (Werkelijk)

19 oktober 2023

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

14 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Individual participant data will not be shared with external researchers because the participant information and consent form limits research access to those formally affiliated with the KeDA trial.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren